BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 29057879)

  • 21. Common Genomic Aberrations in Mouse and Human Breast Cancers with Concurrent P53 Deficiency and Activated PTEN-PI3K-AKT Pathway.
    Martinez JD; Mo Q; Xu Y; Qin L; Li Y; Xu J
    Int J Biol Sci; 2022; 18(1):229-241. PubMed ID: 34975329
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cutting Edge: Foxp1 Controls Naive CD8+ T Cell Quiescence by Simultaneously Repressing Key Pathways in Cellular Metabolism and Cell Cycle Progression.
    Wei H; Geng J; Shi B; Liu Z; Wang YH; Stevens AC; Sprout SL; Yao M; Wang H; Hu H
    J Immunol; 2016 May; 196(9):3537-41. PubMed ID: 27001958
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer.
    Sircar K; Yoshimoto M; Monzon FA; Koumakpayi IH; Katz RL; Khanna A; Alvarez K; Chen G; Darnel AD; Aprikian AG; Saad F; Bismar TA; Squire JA
    J Pathol; 2009 Aug; 218(4):505-13. PubMed ID: 19402094
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Crosstalking between androgen and PI3K/AKT signaling pathways in prostate cancer cells.
    Lee SH; Johnson D; Luong R; Sun Z
    J Biol Chem; 2015 Jan; 290(5):2759-68. PubMed ID: 25527506
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activation of Akt signaling in prostate induces a TGFβ-mediated restraint on cancer progression and metastasis.
    Bjerke GA; Yang CS; Frierson HF; Paschal BM; Wotton D
    Oncogene; 2014 Jul; 33(28):3660-7. PubMed ID: 23995785
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acid ceramidase promotes nuclear export of PTEN through sphingosine 1-phosphate mediated Akt signaling.
    Beckham TH; Cheng JC; Lu P; Marrison ST; Norris JS; Liu X
    PLoS One; 2013; 8(10):e76593. PubMed ID: 24098536
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis.
    Song H; Zhang B; Watson MA; Humphrey PA; Lim H; Milbrandt J
    Oncogene; 2009 Sep; 28(37):3307-19. PubMed ID: 19597465
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Loss of PTEN stabilizes the lipid modifying enzyme cytosolic phospholipase A₂α via AKT in prostate cancer cells.
    Vignarajan S; Xie C; Yao M; Sun Y; Simanainen U; Sved P; Liu T; Dong Q
    Oncotarget; 2014 Aug; 5(15):6289-99. PubMed ID: 25026288
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling.
    Conley-LaComb MK; Saliganan A; Kandagatla P; Chen YQ; Cher ML; Chinni SR
    Mol Cancer; 2013 Jul; 12(1):85. PubMed ID: 23902739
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Integrative analysis of FOXP1 function reveals a tumor-suppressive effect in prostate cancer.
    Takayama K; Suzuki T; Tsutsumi S; Fujimura T; Takahashi S; Homma Y; Urano T; Aburatani H; Inoue S
    Mol Endocrinol; 2014 Dec; 28(12):2012-24. PubMed ID: 25329375
    [TBL] [Abstract][Full Text] [Related]  

  • 31. mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice.
    Guertin DA; Stevens DM; Saitoh M; Kinkel S; Crosby K; Sheen JH; Mullholland DJ; Magnuson MA; Wu H; Sabatini DM
    Cancer Cell; 2009 Feb; 15(2):148-59. PubMed ID: 19185849
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FOXP1 acts through a negative feedback loop to suppress FOXO-induced apoptosis.
    van Boxtel R; Gomez-Puerto C; Mokry M; Eijkelenboom A; van der Vos KE; Nieuwenhuis EE; Burgering BM; Lam EW; Coffer PJ
    Cell Death Differ; 2013 Sep; 20(9):1219-29. PubMed ID: 23832113
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proproliferative function of adaptor protein GRB10 in prostate carcinoma.
    Khan MI; Al Johani A; Hamid A; Ateeq B; Manzar N; Adhami VM; Lall RK; Rath S; Sechi M; Siddiqui IA; Choudhry H; Zamzami MA; Havighurst TC; Huang W; Ntambi JM; Mukhtar H
    FASEB J; 2019 Mar; 33(3):3198-3211. PubMed ID: 30379590
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytosolic phospholipase A2α sustains pAKT, pERK and AR levels in PTEN-null/mutated prostate cancer cells.
    Hua S; Yao M; Vignarajan S; Witting P; Hejazi L; Gong Z; Teng Y; Niknami M; Assinder S; Richardson D; Dong Q
    Biochim Biophys Acta; 2013 Jun; 1831(6):1146-57. PubMed ID: 23500889
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.
    Yuen HF; Chan KK; Grills C; Murray JT; Platt-Higgins A; Eldin OS; O'Byrne K; Janne P; Fennell DA; Johnston PG; Rudland PS; El-Tanani M
    Clin Cancer Res; 2012 Jan; 18(2):380-91. PubMed ID: 22090358
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of
    Pearson HB; Li J; Meniel VS; Fennell CM; Waring P; Montgomery KG; Rebello RJ; Macpherson AA; Koushyar S; Furic L; Cullinane C; Clarkson RW; Smalley MJ; Simpson KJ; Phesse TJ; Shepherd PR; Humbert PO; Sansom OJ; Phillips WA
    Cancer Discov; 2018 Jun; 8(6):764-779. PubMed ID: 29581176
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PLEKHS1 drives PI3Ks and remodels pathway homeostasis in PTEN-null prostate.
    Chessa TAM; Jung P; Anwar A; Suire S; Anderson KE; Barneda D; Kielkowska A; Sadiq BA; Lai IW; Felisbino S; Turnham DJ; Pearson HB; Phillips WA; Sasaki J; Sasaki T; Oxley D; Spensberger D; Segonds-Pichon A; Wilson M; Walker S; Okkenhaug H; Cosulich S; Hawkins PT; Stephens LR
    Mol Cell; 2023 Aug; 83(16):2991-3009.e13. PubMed ID: 37567175
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PTEN Protein Phosphatase Activity Is Not Required for Tumour Suppression in the Mouse Prostate.
    Wise HM; Harris A; Kriplani N; Schofield A; Caldwell H; Arends MJ; Overton IM; Leslie NR
    Biomolecules; 2022 Oct; 12(10):. PubMed ID: 36291720
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth.
    Blando J; Portis M; Benavides F; Alexander A; Mills G; Dave B; Conti CJ; Kim J; Walker CL
    Am J Pathol; 2009 May; 174(5):1869-79. PubMed ID: 19395652
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Deregulated PTEN/PI3K/AKT/mTOR signaling in prostate cancer: Still a potential druggable target?
    Braglia L; Zavatti M; Vinceti M; Martelli AM; Marmiroli S
    Biochim Biophys Acta Mol Cell Res; 2020 Sep; 1867(9):118731. PubMed ID: 32360668
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.